Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study

被引：2
|
作者：
Ouyang, Fengchen
机构：
[1] Xi'an, Shaanxi
来源：
RHEUMATOLOGY | 2022年 / 61卷 / 10期
关键词：
D O I：
10.1093/rheumatology/keac330
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E320 / E320
页数：1
相关论文
共 50 条
  • [1] Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply
    Vegas, Laura Pina
    Claudepierre, Pascal
    Sbidian, Emilie
    RHEUMATOLOGY, 2022, 61 (08) : E238 - E239
  • [2] Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study
    Vegas, Laura Pina
    Le Corvoisier, Philippe
    Penso, Laetitia
    Paul, Muriel
    Sbidian, Emilie
    Claudepierre, Pascal
    RHEUMATOLOGY, 2022, 61 (04) : 1589 - 1599
  • [3] Comment on: Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study: Reply
    Pina Vegas, Laura
    Claudepierre, Pascal
    Sbidian, Emilie
    RHEUMATOLOGY, 2022, 61 (10) : E321 - E322
  • [4] RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS INITIATING BIOLOGICS/APREMILAST FOR PSORIATIC ARTHRITIS: A NATIONWIDE POPULATION-BASED STUDY USING THE FRENCH HEALTH INSURANCE DATABASE
    Vegas, L. Pina
    Le Corvoisier, P.
    Penso, L.
    Paul, M.
    Sbidian, E.
    Claudepierre, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 317 - 317
  • [5] Cardiovascular Risk Markers and Major Adverse Cardiovascular Events in Psoriatic Arthritis Patients
    Peluso, Rosario
    Caso, Francesco
    Tasso, Marco
    Ambrosino, Pasquale
    Di Minno, Matteo Nicola Dario
    Lupoli, Roberta
    Criscuolo, Livio
    Caso, Paolo
    Ursini, Francesco
    Del Puente, Antonio
    Scarpa, Raffaele
    Costa, Luisa
    REVIEWS ON RECENT CLINICAL TRIALS, 2018, 13 (03) : 199 - 209
  • [6] RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN A SWISS COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLARTHRITIS
    Lauper, K.
    Chevallier-Ruggeri, P.
    Finckh, A.
    Gabay, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 702 - 703
  • [7] Comment on: The risk of major adverse cardiovascular events in patients with systemic sclerosis: a nationwide, population-based cohort study
    Chen, Fang-Yu
    Huo, An-Ping
    Wei, James Cheng-Chung
    RHEUMATOLOGY, 2024, 63 (08) : e236 - e236
  • [8] Comment on: The risk of major adverse cardiovascular events in patients with systemic sclerosis: a nationwide, population-based cohort study: Reply
    Yen, Tsai-Hung
    Chen, Hsin-Hua
    RHEUMATOLOGY, 2024, 63 (08) : e234 - e235
  • [9] Rates of major adverse cardiovascular events (MACE) and revascularization among patients with psoriasis or psoriatic arthritis treated with apremilast, biologics, DMARDs, and corticosteroids in the US MarketScan database
    Persson, Rebecca
    Hagberg, Katrina W.
    Qian, Ellen
    Vasilakis-Scaramozza, Catherine
    Niemcryk, Steve
    Peng, Michael
    Paris, Maria
    Lindholm, Anders
    Jick, Susan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 474 - 474
  • [10] The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids
    Persson, Rebecca
    Hagberg, Katrina Wilcox
    Qian, Yiran
    Vasilakis-Scaramozza, Catherine
    Jick, Susan
    RHEUMATOLOGY, 2021, 60 (04) : 1926 - 1931
12345